Tag - BIXT

Developments

Bioxytran completes $1.2 million private placement

Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the company issued...

March 20, 2026

Developments

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...

February 13, 2026

Feature

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics

Bioxytran Inc. (OTCQB: BIXT) is pioneering the use of complex carbohydrate-based therapeutics to address urgent unmet medical needs in virology, cancer metastasis, and oxygen transport.

July 29, 2025

Developments

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Bioxytran (QTCQB:BIXT) announced that it has signed a non-disclosure agreement (NDA) with the board of regents of the University System of Georgia, University of Georgia (UGA), to collaborate on evaluating its galectin...

March 19, 2025

Tag - BIXT

Bioxytran completes $1.2 million private placement

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran disrupting infectious disease and inflammation with carbohydrate-based therapeutics

Bioxytran signs NDA with UGA to evaluate galectin antagonist for bird flu

Subscribe